BackImmunoCellular Therapeutics, Overview

ImmunoCellular Therapeutics, Current Cash

ImmunoCellular Therapeutics,'s current cash is $0.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$0.00
100.00% YoYΔ $-551176.00 vs prior year quarter

Peer average

Loading

ImmunoCellular Therapeutics, Current Cash History

Loading

ImmunoCellular Therapeutics, vs. peers: Current Cash Comparison

Loading

ImmunoCellular Therapeutics, Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ImmunoCellular Therapeutics, (IMUC) FAQ

ImmunoCellular Therapeutics, (IMUC) currently reports a current cash of $0 as of September 2023. That compares with $550K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore ImmunoCellular Therapeutics,'s current cash history and peer comparisons.

ImmunoCellular Therapeutics,'s current cash decreased from $550K to $0 — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoCellular Therapeutics, reported $0 in current cash as of September 2023. That compares with $550K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunoCellular Therapeutics,, and consider following IMUC for alerts when major investors trade the stock.

ImmunoCellular Therapeutics, is classified in the Healthcare sector. On current cash, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMUC with unrelated industries.